tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

OPNT

Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC
Press ReleasesOpiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC
2y ago
OPNT
Opiant Pharmaceuticals announces CFIUS approval for acquisition by Indivior
PremiumThe Fly
Opiant Pharmaceuticals announces CFIUS approval for acquisition by Indivior
2y ago
OPNT
Opiant announces expiration of HSR waiting period for acquisition by Indivior
PremiumThe Fly
Opiant announces expiration of HSR waiting period for acquisition by Indivior
2y ago
OPNT
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC
PremiumPress Releases
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC
2y ago
OPNT
Opiant’s Opioid Therapy Gets Priority Review; PDUFA Date Set for May 22
PremiumMarket News
Opiant’s Opioid Therapy Gets Priority Review; PDUFA Date Set for May 22
2y ago
OPNT
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
PremiumPress ReleasesOpiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
2y ago
OPNT
Opiant announces FDA acceptance, priority review of NDA of OPNT003
Premium
The Fly
Opiant announces FDA acceptance, priority review of NDA of OPNT003
2y ago
OPNT
Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose
Premium
Press Releases
Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose
2y ago
OPNT
Indivior to acquire Opiant Pharmaceuticals for $20.00 per share
PremiumThe Fly
Indivior to acquire Opiant Pharmaceuticals for $20.00 per share
2y ago
OPNT
Opiant Pharmaceuticals reports Q3 EPS ($1.93), consensus ($1.49)
PremiumThe Fly
Opiant Pharmaceuticals reports Q3 EPS ($1.93), consensus ($1.49)
2y ago
OPNT
Opiant (OPNT) Stock Skyrockets on Indivior’s $145M Buyout Offer
PremiumMarket News
Opiant (OPNT) Stock Skyrockets on Indivior’s $145M Buyout Offer
2y ago
OPNT
Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results
PremiumPress Releases
Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results
2y ago
OPNT
Indivior To Acquire Opiant Pharmaceuticals
PremiumPress ReleasesIndivior To Acquire Opiant Pharmaceuticals
2y ago
OPNT
Indivior To Acquire Opiant Pharmaceuticals
Premium
Press Releases
Indivior To Acquire Opiant Pharmaceuticals
2y ago
OPNT
Indivior PLC to Acquire Opiant Pharmaceuticals
Premium
Press Releases
Indivior PLC to Acquire Opiant Pharmaceuticals
2y ago
OPNT
Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022
PremiumPress Releases
Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022
2y ago
OPNT
Opiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder
PremiumPress Releases
Opiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder
2y ago
OPNT
Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis Syndrome
PremiumPress Releases
Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis Syndrome
2y ago
OPNT
Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update
PremiumPress Releases
Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update
2y ago
OPNT
Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal Nalmefene
PremiumPress ReleasesOpiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal Nalmefene
2y ago
OPNT
Teva Wins Court Ruling Against Opiant, Emergent Bio On Narcan Nasal Spray
Premium
Market News
Teva Wins Court Ruling Against Opiant, Emergent Bio On Narcan Nasal Spray
4y ago
EBS
OPNT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >